Inovio Pharmaceuticals Inc.

INO | NASDAQ

Price Alert Chart Builder DCF Calculator

$1.30

+$0.06 (+4.84%)

Sep 22, 2026, 11:07 AM ET · Market open

Overview Rating Statistics Financials Earnings Analysts Ownership Profile

+4.84%

(1D)

Rating

Updated: Sep 8, 2026

20.5

Fundamentals Weak

Market Sentiment Bullish

Moat None

Full Analysis

Key Statistics

Market Data

Market Cap $89.82M

1D Range

1.25 1.34

52W Range

0.56 2.72

Valuation (TTM)

PE -1.06

PB 19.60

EV/EBITDA -0.88

Valuation (NTM)

Forward PE N/A

Forward PEG 0.02

Price Target $2.75

Cash Flow

FCF Yield -46314.7%

SBC Adj. FCF Yield -48029.0%

SBC Impact -3.7%

Margins

Gross Margin 0.0%

Operating Margin 0.0%

FCF Margin N/A

Growth (CAGR)

Revenue 3Y | 5Y -114.7% | -54.6%

Dil EPS 3Y | 5Y 0.4% | -49.4%

FCF 3Y | 5Y -148.8% | -98.0%

Returns

ROA -136.5%

ROE -1005.8%

ROIC -640.6%

Financial Health

Net Cash

$36.67M

Current Ratio 1.00

Interest Coverage 0.00

Dividends

Div Yield N/A

Payout Ratio N/A

FCF Payout Ratio N/A

All Key Statistics

Loading financial charts...

Profile

Inovio Pharmaceuticals, Inc. is a biotechnology firm dedicated to the research, development, and market introduction of DNA-based treatments. Its core mission is to prevent and cure illnesses associat...

Sector Healthcare

Industry Biotechnology

Employees 112

IPO Date Dec 7, 1998

Website www.inovio.com

Fiscal Year January - December

Full Company Profile

Latest News

No news articles available yet.

Earnings

Next Earnings

Nov 10, 2026

EPS Est

Pro

Rev Est

Pro

Earnings Details ➞

Analyst Summary

# of Analysts

Consensus

Buy

Price Target

$2.75

Upside

+111.54%

Buy (2)

Hold (1)

Sell (0)

Analyst Details ➞